# ATG-GCSF in New Onset Type 1 Diabetes

> **NCT02215200** · PHASE2 · COMPLETED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 89 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Anti-Thymocyte Globulin (ATG)
- **DRUG:** Granulocyte colony stimulating factor (GCSF)
- **DRUG:** Placebo (for ATG)
- **DRUG:** Placebo (for GCSF)

## Key facts

- **NCT ID:** NCT02215200
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2017-08
- **Final completion:** 2018-08
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2020-03-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02215200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02215200, "ATG-GCSF in New Onset Type 1 Diabetes". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02215200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*